This CPB is revised to state that transcatheter aortic valve implantation by means of an FDA-approved aortic valve (e.g., Medtronic CoreValve System) is considered medically necessary for valve-in-valve replacement persons with a degenerated bioprosthetic aortic valve who require another valve replacement procedure but who have a Society of Thoracic Surgeons operative risk score greater than or equal to 8 % or are judged to be at 15 % or greater risk of mortality for surgical aortic valve replacement.